Key result
Phase 2/3 non-CVOT safety data correctly predict directional CVOT efficacy in ~86% of programs.
Why the study?
The predictive value of phase 2/3 non-CVOT safety assessments for major adverse cardiovascular events on subsequent cardiovascular outcomes trial efficacy of novel cholesterol-lowering drugs was uncertain.
Does MACE safety data from phase 2/3 non-CVOT lipid-lowering studies predict MACE efficacy outcomes in definitive CVOTs?
Systematic Review (n=186,454)
Does MACE safety data from phase 2/3 non-CVOT lipid-lowering studies predict MACE efficacy outcomes in definitive CVOTs?
MACE safety data from short-term phase 2/3 lipid-lowering trials demonstrate unexpected value in predicting the efficacy outcomes of large-scale, definitive cardiovascular outcome trials, potentially aiding in strategic drug development decisions.
Answers are grounded in this paper and cite their sources.
Early MACE monitoring may anticipate CVOT outcomes in lipid-lowering development; leaves open generalizability and prospective validation.
Prior to a cardiovascular outcomes trial (CVOT), novel cholesterol-lowering therapies undergo phase 2/3 studies for their lipid and atherosclerotic effects and safety (non-CVOTs). Since the occurrence of major adverse cardiovascular events (MACE) is part of the safety assessment, nominal reductions or increases may be observed prior to definitive testing of the effect in a CVOT. To investigate the observed MACE treatment effect in non-CVOT lipid-lowering registration studies holds value in predicting the outcome in a CVOT trial, typically reported later than the initial lipid-lowering studies. We reviewed recent development programs for cholesterol-lowering drugs that had completed non-CVOT and CVOT studies. MACE data were compared for phase 2/3 non-CVOT versus pivotal CVOT results. Our primary outcome was a qualitative comparison for directionally concordant consistency in MACE risk ratio treatment effects (harm, neutrality, or benefit). Correlation analysis was also performed. Seven drugs were reviewed in 3 cholesterol-lowering classes: CETP inhibitors, bempedoic acid, and PCSK9 inhibitors. Concordance in non-CVOT vs CVOT results was seen in 6 of 7 drugs. One drug (dalcetrapib) had a trend for benefit observed, albeit with very small numbers, in early development, but showed a neutral CVOT. There was a moderate correlation between the risk reductions or increases from the non-CVOTs and CVOTs: r = 0.69, p = 0.0893. Within the limitations of the drugs studied and the variability in MACE definitions, there is value in the results of non-CVOTs to predict the CVOT outcome.
No takes yet. Share an insight, caveat, or question.
Shear et al. (2026) conducted a systematic review in Hypercholesterolemia and cardiovascular risk (n=186,454). Phase 2/3 non-CVOT MACE safety assessments vs. Pivotal Phase 3 CVOT MACE efficacy outcomes was evaluated on Qualitative directionally concordant consistency in MACE risk ratio treatment effects (harm, neutrality, or benefit) (r = 0.69, p=0.0893). Phase 2/3 non-CVOT major cardiovascular events safety data correctly predicted the directional efficacy outcomes of pivotal CVOTs in 6 out of 7 cholesterol-lowering drug programs.
Synapse has enriched 10 related papers. Consider them for comparative context: